Introduction
Breast cancer is the most common cancer in women worldwide. 1, 2 In Australia, one in eight women will develop breast cancer before the age of 85 2, 3 and in 2015, 15 000 new cases of breast cancer were diagnosed. 1, 3 Males can also be affected, but to a lesser degree. 4 Ovarian cancer is less common with approximately 1 in 78 women developing ovarian cancer before the age of 85. 5 Twenty percent of patients with breast cancer will have a family history of breast and/or ovarian cancer, while between 5% and 10% will have an associated recognisable inherited genetic mutation. 6, 7 Individuals with an inherited mutation are at greater risk of developing not only breast cancer but also ovarian and other cancers and may develop cancer at an earlier age. 7, 8 It is important to identify women who are at high risk of developing breast and/or ovarian cancer, so appropriate screening and interventions can be implemented.
A major role of the ACT Genetic Service is to perform a risk assessment for patients with a personal or family history of breast and/or ovarian cancer, as well as to provide counselling services and facilitate genetic testing. Genetic testing is indicated if the patient has a strong personal or family history of cancer and meets testing guidelines. 9 Referrals to the service are expected to be in accordance with current cancer referral guidelines available to health professionals. The Cancer Institute of New South Wales has developed an online resource, 'eviQ Cancer Guidelines' (available from www.eviq.org. au), 10, 11 which provides best practice guidelines for the management of cancer, including guidelines regarding which patients should be referred for risk assessment and consideration of genetic testing. There are several genetic mutations known to impact on breast and/or ovarian cancer risk that can be tested for. The most common are mutations in BRCA1 and BRCA2 genes, which code for proteins that help repair damaged DNA. Mutations in these genes increase the risk of breast and ovarian cancer. [12] [13] [14] They account for approximately 5-10% of all breast cancers, 12 15-30% of hereditary breast cancers [15] [16] [17] and 15% of epithelial ovarian cancer cases. 18 The risk estimates of the impact of BRCA1 and BRCA2 mutations vary across studies. However, females with a BRCA1 mutation have on average a 60% lifetime risk of developing breast cancer and 40% risk of ovarian cancer. [19] [20] [21] [22] Females with a BRCA2 mutation have on average a 50% lifetime risk of breast cancer and 20% risk of ovarian cancer. [21] [22] [23] [24] Some populations, such as those of Ashkenazi Jewish descent, have a higher prevalence of BRCA1 and BRCA2 mutations. 8 Less common genetic mutations also associated with a high risk of breast cancer, include mutations in the TP53 and PTEN genes, which are key regulators of the cell cycle and apoptosis. 12, [25] [26] [27] Mutations in other genes, such as PALB2, CHEK2, ATM, NBS1, RAD50 and BRIP1, are classified as moderate risk, with an approximate doubling of breast cancer risk compared with the general population. [28] [29] [30] An increased risk of ovarian cancer is also seen in Lynch syndrome, which is caused by mutations in DNA mismatch repair genes, including MLH1, MSH2, MSH6, EPCAM and PMS2. 31, 32 Mutations classified as moderate risk were not as commonly screened for during our study time period. However, mutations in ATM, PALB2 and genes involved in Lynch syndrome also now have clinical risk management guidelines. [33] [34] [35] Patients found to have a genetic mutation are much more likely to develop breast and/or ovarian cancer than the general population. Those individuals who are classified as high-risk have opportunities for enhanced screening and clinical interventions. For example, high-risk individuals under 50 years of age are offered breast MRI screening, which has greater sensitivity than mammographic screening in this age cohort. 36 Additionally, high-risk patients may be offered risk-reducing surgeries such as mastectomy (to reduce risk of breast cancer) and bilateral salpingo-oophorectomy (to reduce risk of both breast and ovarian cancer). These procedures have been shown to reduce the lifetime risk of both breast and ovarian cancer. 37, 38 Chemoprevention drugs, which lower the risk of breast cancer (e.g. tamoxifen), 39 may also be considered in high-risk patients. 40 Early identification of at-risk individuals improves patient outcomes, reinforces positive health behaviours and, importantly, allows family members to be identified and screened. 7 Breast and ovarian cancer referrals make up a significant proportion of referrals to the ACT Genetic Service. They contribute approximately 70% of all cancer referrals, and 50% of total referrals. Demand on the ACT Genetic Service has increased in recent years and the purpose of this audit was to evaluate the current functioning of the service. In particular, the audit looked at the referral practice for patients with a personal or family history of breast and/or ovarian cancer, to assess whether these referrals were made according to current eviQ cancer referral guidelines.
Methods

Study design
A retrospective audit of all patients with a personal and/or family history of breast and/or ovarian cancer, who presented to the ACT Genetic Service at The Canberra Hospital for evaluation of genetic risk between 1 January 2013 and 30 June 2015. This study was 
Data collection and analysis
A list of eligible patients was generated by searching the ACT Genetic Service database for any patients referred for assessment of risk for breast or ovarian cancer during the time period. Patients were excluded if they were referred for another indication or if the file could not be located. De-identified data were collected, including demographic information, referral details (including who referred and whether the referral met referral guidelines) and the outcomes of each appointment (including whether genetic testing was offered and the outcomes of testing). There were three testing outcomes: (i) a positive result, where a known pathogenic mutation was discovered; (ii) a negative result, where a specific predictive familial or founder mutation screen is done and no mutation was found; or (iii) an uninformative result, where no mutations were detected with the current technology, or a variant of unknown clinical significance was found. For the purposes of this study both negative and uninformative results were classified as negative. Pearson Chi-squared and Poisson regression tests were performed using IBM SPSS Statistics for Mac (version 24) software. Significance was set at P-value <0.05.
eviQ referral guidelines
By referring to the eviQ 'Cancer Genetics: Breast and Ovarian Cancer Referral Guidelines 2014', 10,11 patients were classified as either meeting or not meeting referral guidelines according to their reported personal and family histories of cancer obtained by the genetics service, or in the case of referrals who declined an appointment, from their referral letter. Patients were also classified into three groups: (i) personal history of breast and/or ovarian cancer only; (ii) unaffected individuals with a family history of breast and/or ovarian cancer (and no identified pathogenic mutations); and (iii) unaffected individuals with a family history of breast and/or ovarian cancer with an identified pathogenic mutation in the family.
Results
A total of 857 files was identified from the ACT Genetic Service database. One hundred and forty-six files did not meet the inclusion criteria, therefore the total number of eligible patients referred to the service during the 30-month time period was 711. Forty (5.6%) of the patients offered an appointment declined to attend. Therefore, the total number of patients seen by the service was 671. The number of patients seen during each consecutive 6-month period increased steadily since 2013 (Table 1) .
Patient demographics
A total of 669 (94%) of referred patients was female, with a median age of 47 years. Data on place of birth were available for 234 (33%) patients and of those, the majority, 197 (84%) patients, were born in Australia. Ethnicity was recorded for 387 (54%) patients, of whom 229 (59%) were of English or Anglo-Saxon background.
Referral waiting times
The length of time between the date the referral was sent and the patients' first appointment was available for 610 (91%) of patients. In the remaining cases, either the referral date or the date of first appointment was not recorded. Waiting times increased significantly over the time period (P-value <0.01). The median waiting time in early 2013 was 4.3 months, compared with 9.8 months in 2015. Additionally, the percentage of patients who waited more than 12 months to be seen has significantly increased, from 3% in early 2013 to 41% in 2015.
Referral source
Over half the referrals, 403 (57%), came from general practitioners (GPs). Oncologists (including medical, radiation and gynaecological oncologists) referred 172 (24%) patients, while the remaining 136 referrals (19%) came from genetic counsellors (33), obstetricians and/or gynaecologists (29) , radiologists (27) , surgeons (23) and others (24) . The other category includes breast care nurses, midwives and self-referrals. 
Adherence to referral guidelines
Of the 711 patients referred to the service, 411 (58%) were referred according to eviQ guidelines and 300 (42%) were not. Genetic counsellors were the most likely to refer according to guidelines (97%), while oncologists were the least likely, with only 50% of referrals meeting guidelines. Additionally, a significant proportion of GP referrals did not meet guidelines, with only 55% of referrals made per guidelines (Table 2) . Of the 671 patients seen by the service, 237 (35%) were referred based on having a personal history of cancer, 313 (46%) of patients were referred based on their family history of breast and/or ovarian cancer but no identified mutations and 121 (18%) of patients had a family history of breast and/or ovarian cancer and an already identified pathogenic mutation in the family. Of these groups, patients with a family history of cancer only and no identified mutations were the least likely to meet referral guidelines (48% ; Table 3 ). Last, it is important to note that concordance with guidelines has not improved over time (Table 1) .
Genetic testing
A total of 267 (38%) patients, whose personal or family history of breast and/or ovarian cancer suggested an inherited component, was offered genetic testing, of whom 10 declined. Of the 257 tests, 82 (32%) had a positive result. Patients who were referred according to eviQ referral guidelines, and specifically those with an already identified pathogenic mutation in the family, were not only more likely to be offered testing, but were also more likely to have a positive result (P-value <0.01). Despite making up the majority of referrals to the service, patients with a family history only and no identified mutations were less likely both to be offered testing (7%) and to have a positive test result (0.6%), when compared with patients with a personal history of cancer or those with an identified pathogenic mutation in the family (Tables 3, 4) .
Of note, 34 patients who did not meet eviQ referral guidelines were offered genetic testing. The reasons that testing was offered include, first, that many of these patients were close to meeting guidelines (23/34; 67%) and therefore a conservative approach appears to have been taken by the service. Second, some patients were offered testing for another indication (namely Lynch syndrome; 8/34; 24%) and last, in a small number of cases (3/34; 9%), testing was used to guide treatment options. Interestingly, most of these patients would now qualify for referral under the October 2015 updated eviQ guidelines (26/34; 76%), indicating that referral guidelines have become more inclusive.
Discussion
This audit has provided a general overview of the assessment and management of breast and ovarian cancer referrals to the ACT Genetic Service. The key findings were that demand on the service has been increasing and at the same time, so has the proportion of referrals not meeting national referral guidelines. Oncologists and GPs refer the majority of patients to the service and are also the most likely to refer inappropriately. There have been relatively few studies on the adherence of medical specialists, and in particular oncologists, to cancer genetics referral guidelines. However, those performed show similar results. A study from the Netherlands demonstrated that cancer genetic referral guidelines are not being followed by a significant proportion of specialists, despite being well-versed in genetic risk factors. 41 Additionally, an American study examined adherence to guidelines by clinicians in primary care and showed that many refer moderate risk individuals, and do not refer all high-risk individuals, despite being aware of guidelines and using them as a resource. 42 Both studies were in the form of questionnaires to the referring clinicians, asking them to assess their own adherence. In contrast, our study looked at actual adherence to referral guidelines. To our knowledge there are no other Australian studies published on the subject of clinician compliance to cancer referral guidelines.
There may be a number of explanations why physicians refer patients who do not meet guidelines. Past studies have suggested a potential gap in knowledge in primary care about genetic risk factors and correct referral practices, 43, 44 which was likely a driving factor for the development of the eviQ guidelines. Additionally, a study by White et al. 45 showed that 92% of GPs would refer an individual who did not meet referral guidelines if that individual had requested testing, indicating that patient-driven requests are an important factor. Alternatively, it is possible the lack of adherence could be due to deficiencies of the guidelines themselves. However, independent evaluations of the eviQ guidelines suggest that clinicians are aware of and accessing the guidelines. [46] [47] [48] [49] Additionally, the guidelines are recommended as a useful resource in the literature. 50 Last, we considered patient-specific factors that may influence referral. A key component of the genetic counsellors' consultation with the patient is the initial risk assessment. This provides an individual estimate of the risk of developing breast and/or ovarian cancer in relation to the general population. Past research has shown that this component of the consultation reduces anxiety 51 and psychological distress. 52 Additionally, after genetic counselling, patients are much clearer about their level of risk. 51 It is possible that some lower risk referrals, who do not meet referral guidelines, are made because clinicians recognise the benefit of the psychological component of the assessment.
The strengths of this study include the relatively large sample size, and the completeness of the data set, representing all referrals for the ACT region over the time period. The main limitation is the retrospective nature of the study, which resulted in some missing data and also limited our ability to determine the reason for referral when made outside guidelines. We can therefore only speculate that the large number of 'inappropriate' referrals were either as a result of a knowledge deficiency or due to an awareness of the benefits of risk assessment in lower risk patients.
It is clear that the impact of receiving referrals outside of the guidelines is significant in terms of workload for the department. The ACT Genetic Service currently has 4.2 full-time genetic counsellors to manage both new and existing patients. Given that breast and ovarian cancer referrals make up approximately 50% of their workload, the service has the potential to become overwhelmed, and there are already markers of that with the increase in waiting times. With a limited resource, decisions need to be made to ensure that those most likely to benefit are seen in a reasonable time frame.
In our patient cohort, the eviQ guidelines were very good at identifying individuals who have a low chance of receiving a positive genetic test result. Of all patients referred outside guidelines, only a small proportion were offered genetic testing and only one individual tested positive. Given the effectiveness of the eviQ guidelines perhaps they could be used as a screening tool to ensure, in a service that may be struggling to keep up with the demand, that resources are targeted to those who are most likely to benefit.
A key area for future research is evaluating further the reasons why so many referrals are made outside of the eviQ guidelines, in particular by oncologists and GPs. *P-value < 0.01. †A total of 267 (39%) patients were offered testing; however, 10 decided not to proceed with testing.
Evaluation of cancer referral guidelines
Conclusion
This audit of breast and ovarian cancer referrals to the ACT Genetic Service disclosed a steady increase in referrals, with the resultant increase in waiting times. Importantly, it also demonstrates that a significant proportion of referrals are made outside of eviQ referral guidelines. The guidelines were shown to discriminate effectively the likelihood of a patient undergoing a genetic test, and also having a positive result. Although the reasons for referral outside guidelines can only be postulated, they may include lack of knowledge, an intention to have moderate risk factors assessed, or a desire to reassure the patient or provide psychosocial support. Further research in this area is warranted. However, in a system that is struggling to meet the demand for referrals in a timely fashion, it seems appropriate to consider using the eviQ guidelines to triage patients and prioritise referrals to those most likely to warrant genetic testing.
